Diversity in a simple co-crystal: racemic and kryptoracemic behaviourElectronic supplementary information (ESI) available: Experimental procedures and analytical data. CCDC 1480079-1480081. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c6cc04148e
The crystal structure containing (±)-3-methyl-2-phenylbutyramide with salicylic acid is the first example of a kryptoracemate co-crystal. It exhibits the first temperature mediated reversible single-crystal to single-crystal transition between two kryptoracemate forms, in addition to crystallising i...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Journal Article |
Published |
23.06.2016
|
Online Access | Get full text |
Cover
Loading…
Summary: | The crystal structure containing (±)-3-methyl-2-phenylbutyramide with salicylic acid is the first example of a kryptoracemate co-crystal. It exhibits the first temperature mediated reversible single-crystal to single-crystal transition between two kryptoracemate forms, in addition to crystallising in another, racemic, form. Theoretical calculations and structural analysis reveal that there are only small differences in both energy and packing arrangements between the three forms. These results suggest that co-crystals can be an opportunity to investigate kryptoracemate behaviour.
The first kryptoracemate co-crystal displays structural diversity and a reversible single-crystal to single-crystal transition between two kryptoracemate forms. |
---|---|
Bibliography: | Electronic supplementary information (ESI) available: Experimental procedures and analytical data. CCDC 1480079-1480081 For ESI and crystallographic data in CIF or other electronic format see DOI 10.1039/c6cc04148e |
ISSN: | 1359-7345 1364-548X |
DOI: | 10.1039/c6cc04148e |